FDA to target addictive levels of nicotine in cigarettes
For the first time, the federal government is proposing cutting the nicotine level in cigarettes so they aren't so addictive.
U.S. Food and Drug Administration chief Scott Gottlieb on Friday directed the agency's staff to develop new regulations on nicotine. The FDA has had the power since 2009 to regulate nicotine levels but hasn't done so. Stocks of cigarette makers plunged after the announcement.
As part of the new strategy, the FDA is giving e-cigarette makers four more years to comply with a review of products already on the market, Gottlieb said. The agency intends to write rules that balance safety with e-cigarettes' role in helping smokers quit, he said.
"A renewed focus on nicotine can help us to achieve a world where cigarettes no longer addict future generations of our kids," Gottlieb said in a speech to staff in Silver Spring, Maryland.
Tar and other substances inhaled through smoking make cigarettes deadly, but the nicotine in tobacco is what makes them addictive.
Tobacco use is the leading cause of preventable heart disease, cancer and death in the United States, causing more than 480,000 deaths annually. Smoking rates, though, have been falling for decades and are at about 15 percent.
Gottlieb said he has asked the FDA's Center for Tobacco Products to explore whether lowering nicotine could create a black market for higher nicotine products and what role e-cigarettes and other products play in reducing harm from smoking. Battery-powered e-cigarettes turn liquid nicotine into an inhalable vapor. He also wants new rules to address flavored tobacco products and kids.
The FDA announcement is great news, said Eric Donny, a University of Pittsburgh researcher who has studied what happens when smokers puff on cigarettes with lower levels of nicotine. Donny and other researchers found that reducing nicotine substantially — by around 90 percent — leads to smokers being less dependent on cigarettes and smoking fewer of them.
There have been concerns that smokers might react to lower nicotine levels by smoking more. But the research shows that's not what happens — not if enough nicotine is taken out, Donny said.
"Most of the harm associated with smoking is related not to the nicotine but everything else in the smoke. Reducing nicotine doesn't make a cigarette safe, it just makes it less addictive," said Donny, director of Pitt's Center for the Evaluation of Nicotine in Cigarettes.
There's additional research underway to see how often people who smoke lower-nicotine cigarettes switch to e-cigarettes or other, less harmful tobacco products, he said.
Kenneth Warner, a retired University of Michigan public health professor who is a leading authority on smoking and health, said he was pleasantly surprised to learn of the FDA announcement.
"If you can separate the nicotine people are craving from the smoke that's killing them, then you may be doing something very important," Warner said.
Campaign for Tobacco-Free Kids president Matthew Myers praised the overall approach as "a bold and comprehensive vision" but called the e-cigarettes delay "a serious error."
"This long delay will allow egregious, kid-friendly e-cigarettes and cigars, in flavors like gummy bear, cherry crush and banana smash, to stay on the market with little public health oversight," Myers said in a statement.
Altria Group, which sells Marlboro, other brands and e-cigarettes in the U.S., said it would be "fully engaged" in FDA's rule-making process.
"It's important to understand that any proposed rule such as a nicotine product standard must be based on science and evidence, must not lead to unintended consequences and must be technically achievable," the company said in a statement.
Gottlieb touched on premium cigars in his announcement, saying the agency wants to hear from the industry about their patterns of use and public health impacts. He said the FDA will "seriously consider" new data relevant to how premium cigars should be regulated.
___
AP Medical Writer Mike Stobbe contributed from New York.